Anti-N-methyl-D-aspartate-receptor encephalitis: diagnosis, optimal management, and challenges

Autor: Mann AP, Grebenciucova E, Lukas RV

Publikováno v: Therapeutics and Clinical Risk Management, Vol 2014, Iss default, Pp 517-525 (2014)

Andrea P Mann,1 Elena Grebenciucova,2 Rimas V Lukas21Department of Psychiatry and Behavioral Neuroscience, 2Department of Neurology, University of Chicago, Chicago, IL, USAObjective: Anti-N-methyl-D-aspartate-receptor (NMDA-R) encephalitis is a new a

Externí odkaz: https://doaj.org/article/20712d7c81894807a47365e50812d7e7

SUGAR INDUSTRY ABSTRACTS - Improvements to bagasse combustion.

Autor: Mann, AP (AUTHOR)

Publikováno v: Pakistan Sugar Journal. Oct-Dec2020, Vol. 35 Issue 4, p16-16. 1p.

Immune-mediated ECM depletion improves tumour perfusion and payload delivery.

Autor: Yeow YL; Harry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia., Kotamraju VR; Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA., Wang X; Harry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia., Chopra M; Harry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia., Azme N; Harry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia., Wu J; Harry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia., Schoep TD; Telethon Kids Institute, Subiaco, WA, Australia., Delaney DS; Harry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia., Feindel K; Centre for Microscopy, Characterisation & Analysis, The University of Western Australia, Perth, WA, Australia., Li J; Harry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia., Kennedy KM; Department of Electrical, Electronic & Computer Engineering, School of Engineering, The University of Western Australia, Perth, WA, Australia., Allen WM; Harry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia.; Department of Electrical, Electronic & Computer Engineering, School of Engineering, The University of Western Australia, Perth, WA, Australia., Kennedy BF; Harry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia.; Department of Electrical, Electronic & Computer Engineering, School of Engineering, The University of Western Australia, Perth, WA, Australia., Larma I; Centre for Microscopy, Characterisation & Analysis, The University of Western Australia, Perth, WA, Australia., Sampson DD; Centre for Microscopy, Characterisation & Analysis, The University of Western Australia, Perth, WA, Australia.; Department of Electrical, Electronic & Computer Engineering, School of Engineering, The University of Western Australia, Perth, WA, Australia., Mahakian LM; Department of Biomedical Engineering, University of California Davis, Davis, CA, USA., Fite BZ; Department of Biomedical Engineering, University of California Davis, Davis, CA, USA., Zhang H; Department of Biomedical Engineering, University of California Davis, Davis, CA, USA., Friman T; Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA., Mann AP; Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA., Aziz FA; Sir Charles Gairdner Hospital, Perth, WA, Australia., Kumarasinghe MP; PathWest Laboratory Medicine, QE2 Medical Centre, Perth, WA, Australia., Johansson M; Sir Charles Gairdner Hospital, Perth, WA, Australia., Ee HC; Sir Charles Gairdner Hospital, Perth, WA, Australia., Yeoh G; Harry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia., Mou L; Sir Charles Gairdner Hospital, Perth, WA, Australia., Ferrara KW; Department of Biomedical Engineering, University of California Davis, Davis, CA, USA., Billiran H; Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA., Ganss R; Harry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia., Ruoslahti E; Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA., Hamzah J; Harry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia.

Publikováno v: EMBO molecular medicine [EMBO Mol Med] 2019 Dec; Vol. 11 (12), pp. e10923. Date of Electronic Publication: 2019 Nov 11.

Publisher Correction: Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease.

Autor: Mann AP; Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA., Scodeller P; Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.; Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, 50411, Estonia., Hussain S; Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.; AivoCode Inc, La Jolla, CA, 92037, USA., Braun GB; Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA., Mölder T; Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, 50411, Estonia., Toome K; Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, 50411, Estonia., Ambasudhan R; Neurodegenerative Disease Center, Scintillon Institute, San Diego, CA, 92121, USA., Teesalu T; Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, 50411, Estonia., Lipton SA; Neurodegenerative Disease Center, Scintillon Institute, San Diego, CA, 92121, USA.; Department of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, CA, 92093, USA., Ruoslahti E; Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA. ruoslahti@sbpdiscovery.org.; Center for Nanomedicine and Department of Cell, Molecular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA. ruoslahti@sbpdiscovery.org.

Publikováno v: Nature communications [Nat Commun] 2018 Mar 09; Vol. 9 (1), pp. 1070. Date of Electronic Publication: 2018 Mar 09.

Clinical pathway development to standardize pharmacological medication management of agitation in pediatric inpatient settings.

Autor: Wood, Michael D.^1,2 (AUTHOR), Gandhi, Kavi² (AUTHOR), Elbe, Dean^3,4,5 (AUTHOR) delbe@cw.bc.ca, Saran, Kelly^3,5 (AUTHOR), Leung, Sarah⁴ (AUTHOR), McKay, Joanna³ (NURSE), Carr, Roxane⁴ (AUTHOR), Chapman, Andrea^3,5 (AUTHOR)

Publikováno v: Journal of the Canadian Academy of Child & Adolescent Psychiatry. Jul2024, Vol. 33 Issue 2, p131-144. 14p.